Schizophrenia/Psychosis

New research may help better understand psychosis etiology as well as provide potential biomarkers for psychosis.

Cannabis has been heralded as a treatment for many conditions, but what about its psychiatric risks?

A recent study dives into the data.

Simple but powerful strategies for drawing on patients’ existing character strengths and long-term goals.

This combination treatment of olanzapine and samidorphan caused significantly less weight gain in patients with schizophrenia and bipolar I disorder.

Sleep problems are understudied, underdiagnosed, and undertreated.

There is debate whether schizoaffective disorder is a separate illness or is part of the continuum of schizophrenia and mood disorder spectrum.

This treatment for agitation associated with schizophrenia and bipolar disorder is moving up the FDA ladder…

Because schizophrenia is associated with increased inflammation, studies on the effects of anti-inflammatory statins are warranted.

Two posters presented at the APA virtual meeting demonstrated long-acting injectable positive results, costs savings, and increased telehealth for patients with schizophrenia.

Data presented at the 2021 APA Virtual Annual Meeting show promise for treating schizophrenia.

The sexual side effects of psychiatric medications are troubling enough that some patients consider treatment cessation. The authors review 5 strategies for managing sexual dysfunction.

There is evidence for overlapping risk factors and symptomatology between ADHD and psychotic disorders. New research investigates the association between ADHD during childhood and the subsequent risk of developing a psychotic disorder.

Ronald W Pies, MD, considers the evidence from pathology textbooks—and answers the critics.

A lawyer discusses how the legal system treats (and mistreats) those with mental illnesses.

A new risperidone capsule for the treatment of schizophrenia sees positive phase 2 study results.

Patient perspectives in academic discourse in psychiatry have historically been a neglected area. What are some of the consequences and implications of this absence? How has this affected both psychiatry and those who have been excluded? These questions and more are discussed.

A quick primer on nomenclature, issues to consider, and switching.

CRL cites lack of substantial evidence of efficacy needed for approval.

When do cognitive impairments emerge in patients with schizophrenia?

The war experiences of physicians and scientists shaped their research agendas.

A DSM-5 diagnosis requires a biopsychosocial case formulation—not just a symptom checklist.

Aerobic exercise has been found to exert a positive effect on global cognition and some, but not all, cognitive domains in patients with schizophrenia.

What is the long-term, real-world effectiveness of pharmacotherapies for schizoaffective disorder? An investigation into 2 nationwide cohorts of patients living with schizophrenia provides new details.

An antipsychotic changed the life of not only 1 man, but an entire family.

Does switching antipsychotics quell weight gain in patients with severe mental illness? A meta-analysis of 59 relevant studies provides insights.

A synthesis of quantitative reviews on the relationship between cannabis use and psychosis.

The chief medical officer of Karuna shares his thoughts exclusively with Psychiatric Times.

Is it possible to use cognitive testing, which is brief, easily performed, reliable, and noninvasive, to identify individuals at risk for psychosis?